Table 1.
Patient characteristics
| Characteristics | N (%) |
|---|---|
| Mean age (years)±s.d. | 49±14 |
| Sex | |
| Male | 32 (63) |
| Female | 19 (37) |
| Hematologic disease | |
| Acute myeloid leukemia | 13 (25) |
| Non-Hodgkin lymphoma | 11 (21) |
| Multiple myeloma | 7 (14) |
| Amyloidosis | 4 (8) |
| Myelodysplastic syndrome | 4 (8) |
| Acute lymphoblastic leukemia | 3 (6) |
| Chronic lymphoid leukemia | 2 (4) |
| Waldenstrom’s macroglobulinemia | 2 (4) |
| Hodgkin lymphoma | 1 (2) |
| Other hematologic malignancies | 4 (8) |
| Type of HSCT | |
| Allogeneic | 34 (67) |
| Unrelated | 22 (65) |
| Related | 12 (35) |
| Autologous | 17 (33) |
| Stem cell source | |
| Peripheral blood | 43 (84) |
| Bone marrow | 4 (8) |
| Cord blood | 3 (6) |
| Peripheral blood+bone marrow | 1 (2) |
| CMV serostatus | |
| Autologous | 17 (33) |
| Positive | 12 (71) |
| Negative | 5 (29) |
| Allogeneic (recipient–donor) | 34 (67) |
| Positive–negative | 15 (44) |
| Positive–positive | 10 (29) |
| Negative–negative | 6 (18) |
| Negative–positive | 3 (9) |
| Conditioning | |
| RIC | 14 (27) |
| Myeloablative | 37 (73) |
| GvHD prophylaxis strategy | |
| No prophylaxis | 17 (33) |
| Cyclosporine+MTX | 21 (41) |
| Cyclosporine+mycophenolate mofetil | 13 (25) |
Abbreviations: HSCT=hematopoietic stem cell transplantation; MTX=metotrexate; RIC=reduced intensity conditioning.